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575Generation of familial amyloidotic polyneuropathy-pecific induced pluripotent stem cellsAbstract Familial amyloidotic polyneuropathy (FAP) is a hereditary amyloidosis induced by amyloidogenic transthyretin
(ATTR). Because most transthyretin (TTR) in serum is synthesized by the liver, liver transplantation (LT) is today the only
treatment available to halt the progression of FAP, even though LT is associated with several problems. Despite the urgent
need to develop alternatives to LT, the detailed pathogenesis of FAP is still unknown; also, no model fully represents the
relevant processes in patients with FAP. The induction of induced pluripotent stem (iPS) cells has allowed development of
pluripotent cells specific for patients and has led to useful models of human diseases. Because of the need for a tool to
elucidate the molecular pathogenesis of FAP, in this study we sought to establish heterozygous ATTR mutant iPS cells, and were
successful, by using a Sendai virus vector mixture containing four transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) to
reprogram dermal fibroblasts derived from FAP patients. Moreover, FAP-specific iPS cells had the potential to differentiate
into hepatocyte-like cells and indeed expressed ATTR. FAP-specific iPS cells demonstrated the possibility of serving as a
pathological tool that will contribute to understanding the pathogenesis of FAP and development of FAP treatments.© 2014 The Authors. Published by Elsevier B.V. All rights reserved.Introduction
Transthyretin (TTR) is a β-sheet-rich protein that is mainly
synthesized by the liver (Buxbaum and Reixach, 2009). TTR
normally serves as a plasma transport protein for thyroid
hormone and retinol-binding protein with vitamin A (Kanai
et al., 1968). Mutant forms of TTR, however, cause familial
amyloidotic polyneuropathy (FAP), which is the most
common type of autosomal-dominant hereditary systemic
amyloidosis (Saraiva et al., 1983; Ando et al., 2005). As of
today, more than 100 different points of mutation and a
deletion in the TTR gene have been reported (Westermark et
al., 2002; Ando and Ueda, 2012; Benson and Kincaid, 2007),
with the Val30Met mutation being the most common.
Systemic amyloid depositions in FAP cause various symp-
toms, including cardiac and renal dysfunctions, gastrointes-
tinal disorders, glandular and autonomic dysfunctions, and
peripheral neuropathy (Ando and Suhr, 1998; Ando et al.,
1993, 1997; Araki, 1984). Because the liver synthesizes most
of the TTR in the serum, liver transplantation (LT) is the only
treatment available to halt the progression of FAP (Ando et
al., 1995a; Suhr et al., 1995). Although LT is widely accepted
as the only lifesaving treatment option for FAP patients
(Ando et al., 1995b), LT involves several problems, such as a
shortage of liver donors, the effects of immunosuppressants,
and the progression of ocular disorders caused by a
continuing production of amyloidogenic TTR (ATTR) by the
retina (Ong et al., 1994; Kawaji et al., 2005).
Despite an urgent need to develop alternatives to LT,
details about the mechanism of amyloid formation in FAP are
still unknown. Although attempts were made to establish
experimental models of FAP, a suitable tool is not yet
available (Buxbaum et al., 2003; Pokrzywa et al., 2007; Berg
et al., 2009). Because FAP is an autosomal-dominant
inherited disease, TTR secreted into plasma is the
heterotetrameric mixture of wild-type TTR and variant
TTR. However, all TTRs used in experiments have been
homotetramers, and an artificial Val30Met-overexpressed
cell system does not fully represent the relevant processes in
patients with FAP (Sousa et al., 2000; Cardoso et al., 2008;
Sato et al., 2007). Therefore, an urgent need exists to
establish an experimental model such as heterozygous ATTR
mutant cells derived from FAP patients.
Induced pluripotent stem (iPS) cells have an unlimited
replicative ability and the potential to differentiate into most
cell types in organisms (Takahashi and Yamanaka, 2006;Takahashi et al., 2007; Yu et al., 2007). The creation of iPS
cells has permitted the development of patient-specific
pluripotent cells and has led to useful models of human
diseases (Saha and Jaenisch, 2009). Recent studies reported
success in generating patient-specific iPS cells for various
diseases including neurologic (Dimos et al., 2008; Ebert et al.,
2009; Soldner et al., 2009), hematologic (Raya et al., 2009),
and metabolic disorders (Maehr et al., 2009). A report on
spinal muscular atrophy-specific iPS cells suggested applica-
tions to disease modeling and drug screening by showing the
disease-specific changes in cell survival and function (Ebert et
al., 2009). A report on Fanconi anemia-specific iPS cells also
indicated a potential value for cell therapy by correcting the
genetic defect before iPS cell derivation (Raya et al., 2009).
Thus, although disease-specific iPS cells may help therapeutic
research, iPS cells from patients with FAP have not yet been
generated.
In this study, we first report the generation of iPS cells from
patients with FAP ATTR Val30Met, which we achieved by
reprogramming their fibroblasts with a mixture of Sendai
virus (SeV) vector, which does not integrate into the host
genome (Li et al., 2000) and has a low risk of tumorigenicity,
encoding four transcription factors: octamer 3/4 (Oct3/4),
sex-determining region Y box 2 (Sox2), Kruppel-like factor 4
(Klf4), and c-Myc (Fusaki et al., 2009; Ban et al., 2011).
FAP-specific iPS cells indeed differentiated into hepatocyte-
like cells (Shiraki et al., 2008; Shiraki et al., 2011) and
expressed Val30Met ATTR. FAP-specific iPS cells may thus
provide valuable experimental tools to elucidate the molec-
ular pathogenesis of FAPwith a potential value for cell therapy
applications.
Materials and methods
Reagents
Reagents were purchased and used at the designated
concentrations as follows: recombinant human Activin A
(HumanZyme, Chicago, IL), 100 ng/ml; recombinant human
basic fibroblast growth factor (ReproCELL, Yokohama,
Japan); recombinant human Bone morphogenetic protein 4
(R&D systems, Minneapolis, MN), 10 ng/ml; recombinant
human Fibroblast growth factor 10 (PeproTech, London,
UK), 10 ng/ml; recombinant human hepatocyte growth
factor (PeproTech), 10 ng/ml; dexamethasone (Dex;
576 K. Isono et al.Sigma, St. Louis, MO), 1 μM; Y-27632 (Rho-associated kinase
inhibitor; Wako Chemical, Osaka, Japan), 10 μM; Dulbecco's
Modified Eagle Medium (Gibco, Funakoshi, Tokyo, Japan);
RPMI-1640 (Invitrogen, Glasgow, UK); B27 supplement
(Invitrogen), nonessential amino acids (Gibco); L-glutamine
(Gibco); knockout serum replacement (Gibco); polyclonal
rabbit anti-human TTR antibody (Dako, Glostrup, Denmark);
Mouse anti-Oct3/4 antibody (Santa Cruz Biotechnology,
Texas, USA), Rabbit anti-Alphafeto protein antibody
(Dako), Goat anti-human Albumin antibody (Bethyl, Texas,
USA), Goat anti-Sox17 antibody (R&D systems); and Rabbit
anti-HNF-4α antibody (Santa Cruz Biotechnology).Patients
Skin biopsy samples were obtained from three Japanese
female patients with FAP ATTR Val30Met in Kumamoto
University Hospital. All FAP patients in this study had a
definitive diagnosis of FAP on the basis of genetic investiga-
tions and clinical manifestations of FAP (Table 1). The
research followed the guidelines of the Kumamoto Univer-
sity Ethical Committee.Generation of iPS cells
Skin fibroblasts from patients with FAP ATTR Val30Met were
maintained in Dulbecco's Modified Eagle Medium (Gibco)
supplemented with 10% fetal bovine serum. Induction of
human iPS cells was performed as described previously
(Fusaki et al., 2009; Ban et al., 2011). In brief, 1 × 106
human fibroblasts BJ from neonatal foreskin (American Type
Culture Collection, Manassas, VA) or FAP patients' fibroblasts
were infected with conventional SeV vectors carrying Oct3/
4, Sox2, Klf 4, and a temperature-sensitive vector, which has
c-Myc at the HNL position at a multiplicity of infection of 3.
One week after infection, cells were collected and replated
on mitomycin C-treated mouse embryonic fibroblast feeder
cells. The next day, medium was changed to a primate
embryonic stem cell medium supplemented with 10 ng/ml
basic fibroblast growth factor. Embryonic stem cell-like
colonies were picked up 28 days after infection. At passage
3, many colonies were negative for the SeV vector; if the
vector was present, SeV-negative clones were obtained by
incubating cells at nonpermissive temperature (38 °C for
3 days). The reprogramming efficiency was calculated as the
number of alkaline phosphatase (ALP)-positive embryonic
stem cell-like colonies formed per number of infected cells
seeded.Table 1 Characterization of established clones.
Clone no. Fibroblasts Disease P Age/sex
1 BJ Normal 8 Neonatal/
2 Patient A002 FAP 11 51/F
3 Patient A003 FAP 9 33/F
4 Patient A004 FAP 12 44/F
Abbreviations: F, female; FAP, familial amyloidotic polyneuropathy; MDifferentiation into hepatocyte-like cells
FAP-specific iPS cells were differentiated into hepatocyte-like
cells using feeder free method modified from reported
protocols (Shiraki et al., 2008, 2011), with the following
modifications: FAP-specific iPS cells were pretreated over-
night with 10 μM Y-27632 (Wako Chemical) and were then
dissociated by using 0.25% trypsin–EDTA and were plated at
100,000 cells per well in 96-well plates that had been
previously coated with fibronectin. The cells were cultured
for 5 days in DMEM supplemented with 100 ng/ml Activin A
(HumanZyme), 2% B27 supplement (Invitrogen), nonessential
amino acids (Gibco), L-glutamine (Gibco), penicillin and
streptomycin, and β-mercaptoethanol. For differentiation
from D5 to D7, RPMI-1640 (Invitrogen) supplemented with
10 ng/ml BMP4, 10 ng/ml Fgf10 and 2% B27 supplement,
nonessential amino acids (Gibco), L-glutamine (Gibco), peni-
cillin and streptomycin, and β-mercaptoethanol. The medium
was then changed to hepatic differentiation medium-DMEM
supplemented with 10% knockout serum replacement (Gibco),
10 ng/ml hepatocyte growth factor (PeproTech), 1 μM Dex
(Sigma), nonessential amino acids, L-glutamine, penicillin and
streptomycin, and β-mercaptoethanol—for up to 20 days.
Mediumwas replaced every day (Day 0–5) or every 2 days (Day
5–20) with fresh differentiation medium supplemented with
growth factor. Human iPS cell lines (201B7), the first iPS cells
established from human dermal fibroblasts by Dr. Shinya
Yamanaka, and HepG2 cells, a human hepatocellular carcino-
ma cell line, were used as control (Takahashi et al., 2007). For
albumin and TTR secretion assay, definitive endoderm cells
(Day 5) were dissociated with 0.25% trypsin–EDTA (Invitrogen)
and then plated at 200,000 cells/well on a synthemax
(corning) pre-coated 96-well plate, and culture up to Day 20
using the abovementioned protocol.
ALP staining
ALP staining was performed with ALP substrate (1-Step NBT/
BCIP; Pierce, IL, USA) after fixation with 10% neutral
buffered formalin solution (Wako Chemical), as previously
described (Fusaki et al., 2009; Ban et al., 2011).
Reverse-transcription polymerase chain reaction
(RT-PCR) analysis
RNA extraction, cDNA synthesis, and RT-PCR were performed as
described previously (Fusaki et al., 2009; Shiraki et al., 2008).
The following primers were used: NANOG homeobox (NANOG):
forward 5′-TACCTCAGCCTCCAGCAGAT-3′, reverse 5′-TGCGTSeV vector Average induction
efficiency (%)
Established Se
V (–) clones
M Kit 0.46 NT
Kit 0.054 30
Kit 0.41 36
Kit 0.12 33
, male; P, passage; SeV, Sendai virus.
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(TERT): forward 5′-TGCCCGGACCTCCATCAGAGCCAG-3′, re-
verse 5′-TCAGTCCAGGATGGTCTTGAAGTCTG-3′; SeV: forward
5′-TGGCTAAGAACATCGGAAGG-3′, reverse 5′-GTTTTGCAACCA
AGCACTCA-3′; and β-actin: forward 5′-CAACCGCGAGAAGA
TGAC-3′, reverse 5′-AGGAAGGCTGGAAGAGTG-3′.Real-time PCR analysis
The real-time PCR conditions were as follows: denaturation at
95 °C for 15 s and annealing and extension at 60 °C for 60 s,
for up to 40 cycles. Target messenger RNA (mRNA) levels were
expressed as arbitrary units and were determined by using the
standard curve method. The following primers were used:
Oct3/4: forward 5′-AGGTGTGGGGGATTCCCCCAT-3′, reverse
5′-GCGATGTGGCTGATCTGCTGC-3′; Sox17: forward 5′-ACTG
CAACTATCCTGACGTG-3′, reverse 5′-AGGAAATGGAGGAAGCT
GTT-3′; alpha-fetoprotein (AFP): forward 5′-TGCCAACTCA
GTGAGGACAA-3′, reverse 5′-TCCAACAGGCCTGAGAAATC-3′;
albumin (ALB): forward 5′-GATGTCTTCCTGGGCATGTT-3′,
reverse 5′-ACATTTGCTGCCCACTTTTC-3′; TTR: forward 5′-CA
TTCTTGGCAGGATGGCTTC-3′, reverse 5′-CT CCCAGGTGTC
ATCAGCAG-3′; and GAPDH: forward 5′-CGAGATCCCTCCA
AAATCAA-3′, reverse 5′-CATGAGTCCTTCCACGATACCAA-3′.Immunocytochemistry
For whole-mount immunocytochemical analysis, iPS cell
cultures were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) for 30 min, followed by
permeabilization with 0.1% Triton-X (Nakalai Tesque) in PBS
for 10 min at room temperature, rinsed several times with PBS
then incubated with diluted antibody in 20% Blocking One
(Nakalai Tesque) in PBST (0.1% Tween-20 in PBS) in a
humidified chamber overnight at 4 °C. Cells were washed in
PBST, and incubated with secondary antibody in 20% Blocking
One for 2 h at room temperature in the dark. After washing off
the secondary antibody in PBST, cells were counterstained
with 6-diamidino-2-phenylindole (DAPI) (Roche Diagnostics,
Indianapolis, IN). The following antibodies were used as first
antibodies: rabbit anti-AFP (Dako), Goat anti-human Albumin
antibody (Bethyl), anti-Oct3/4 antibody (Santa Cruz Biotech-
nology), goat anti-Sox17 antibody (R&D systems), rabbit
anti-HNF-4α antibody (Santa Cruz Biotechnology), and
anti-HN monoclonal antibody IL4.1 (Fusaki et al., 2009).
Secondary antibodies used were Alexa 568-conjugated and
Alexa 488-conjugated antibodies (Invitrogen). To assess the
efficiency of differentiation, Sox17-, AFP-, and ALB-positive
cells versus total cells (DAPI-positive cells) were quantified
using ImageXpress Micro cellular imaging system (Molecular
Devices Sunnyvale, CA).PAS analysis
The cultured cells were fixed in 3.3% formalin for 10 min,
and intracellular glycogen was stained using a PAS staining
solution (Muto Pure Chemicals, Tokyo, Japan), according to
the manufacturer's instructions.Albumin secretion assay
The differentiation medium was changed to fresh medium
48 h before the assay. Albumin secretion was measured by
the central clinical laboratory at Kumamoto University,
Kumamoto, Japan.
PCR-restriction fragment length polymorphism anal-
ysis (PCR-RFLP)
Extraction of RNA from HepG2 cells and the frozen samples of
livers from FAP patients A002 and cDNA synthesis were
performed as previously described (Fusaki et al., 2009). RNA
was extracted from FAP-specific iPS cells with the RNeasy
Micro Kit (Qiagen, Hilden, Germany) according to the
manufacturer's protocol, and cDNA synthesis was performed
as described elsewhere (Sueyoshi et al., 2012). PCR primers,
which were the same as those used in the real-time PCR
reaction, were designed to amplify the Val30Met mutation in
exon 2 of the TTR gene. The PCR conditions were 5 min at
98 °C; 35 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C
for 1 min; followed by 7 min at 72 °C. The PCR product of
199 bp was digested at 37 °C for 2 h with 5 U Nsi1 restriction
enzyme (New England Biolabs, Ipswich, MA, USA), which
recognized the mutation site. PCR products were evaluated
via a microchip electrophoresis system (Cosmo-I SV1210;
Hitachi Electronics Engineering, Tokyo, Japan). Measurements
were obtained according to the manufacturer's manual.
Surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry (SELDI-TOF MS)
Serum specimens and culture supernatants were evaluated
with the PCS 4000 SELDI-TOF MS instrument (Bio-Rad Labora-
tories, Hercules, CA, USA) by using the following protocol (Ueda
et al., 2009), unless otherwise specified: ion focus mass,
13,800 m/z; laser energy, 2000 nJ;matrix attenuation, 500 m/
z; sample rate, 800; shots/pixel, 5; partition, 1 of 4; and
acquired mass range from 0 to 100,000 m/z. Baseline smooth-
ing: smoothing before fitting baseline, window 25 points.
Baseline width: automatic. These baseline settings were the
default settings. External calibration of the instrument was
performed by using the All-in-One protein molecular mass
standard (Bio-Rad Laboratories). Conditions: Q10 ProteinChip in
50 mmol/l phosphate buffer, pH 7.0.
Liquid chromatography–tandem mass spectrometry
(LC–MS/MS)
The Amicon Ultra centrifugal filter 10 K (Millipore, Billerica,
MA, USA) was used to make 7–10-fold concentrated culture
supernatants. The concentration was incubated overnight at
4 °C with 5 μg of polyclonal rabbit anti-human TTR antibody
(Dako). PureProteome Protein G Magnetic Beads (Millipore)
were added to the reaction to capture the immune complexes
and were agitated for 2 h at 4 °C. After the immune complexes
were washed three times with PBST, 25 μl of sample buffer
(Bio-Rad Laboratories) was added and incubation proceeded for
5 min at 95 °C. Sample buffers (25 μl), which eluted TTR
protein from the beads, were fractionated via sodium dodecyl
Figure 1 SELDI-TOF MS analysis of TTR forms in the serum of an
FAP patient from whom FAP-specific iPS cells were generated.
Peaks at 13,761 and 13,792 Da were free forms of wild-type TTR
and ATTR Val30Met, respectively. Arrows indicate the wild-type
TTR peaks. Asterisks indicate the ATTR Val30Met peaks.
578 K. Isono et al.sulfate-polyacrylamide gel electrophoresis. Silver staining of
gels was performed with ProteoSilverTM Plus Silver Stain Kit
(Sigma-Aldrich) according to the manufacturer's protocol. The
bands of TTR were excised from the gel, destained according to
the manufacturer's protocol, digested with sequence-grade
modified trypsin (Promega, Madison, WI). The peptide mixtures
were dried and redissolved with 40 μl of MS-grade water
containing 0.1% trifluoroacetic acid and 2% acetonitrile, and
were used for nano-flow reversed-phase LC–MS/MS (LTQ Velos
Pro; Thermo Fisher Scientific, San Jose, CA). A capillary
reversed-phase LC–MS/MS system composed of an Advance
Splitless Nano-Capillary LC dual solvent delivery system
(Bruker-Michrom, Auburn, CA), an HTS-xt PAL autosampler
(CTC Analytics, Zwingen, Switzerland), and LTQ Velos Pro
equipped with an XYZ nanoelectrospray ionization source (AMR,
Tokyo, Japan) was used. The samples were injected into a
peptide L-trap column (Chemical Evaluation Research Institute,
Tokyo, Japan). The peptideswere separated by using a capillary
reversed-phase C18 column (Chemical Evaluation Research
Institute) with gradient elution and an ion spray into the mass
spectrometer at a spray voltage of 2.3 kV. The peptide and
fragment mass tolerances were 2.0 Da and 0.8 Da, respective-
ly. To calculate the ratios of wild-type TTR and ATTR to total
TTR in culture supernatants, we measured the areas of the
peptide mass peaks derived from wild-type TTR and ATTR,
respectively. Peptides (22–34 peptides; GSPAINVAVHVFR) de-
rived from wild-type TTR had a molecular mass of 684 m/z.
Peptides (22–34 peptides; GSPAINVAMHVFR) derived from ATTR
had a molecular mass of 700 m/z.
Western blotting
As described in the LC–MS/MS section, the immune complexes,
made from 20-fold concentrated culture supernatants, were
washed three times with PBS, 20 μl of sample buffer (Bio-Rad
Laboratories) was added and incubation proceeded for 5 min at
95 °C. Sample buffers (10 μl), which eluted TTR protein from
the beads, were fractionated via sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to nitrocel-
lulose membranes (GE Healthcare, Buckinghamshire, UK).
Membranes were blocked with 5% nonfat dried milk and PBST
and were then incubated overnight at 4 °C with antibodies
against TTR in 5% bovine serum albumin (Sigma) and PBST. After
the membranes were washed, they were incubated in biotinyl-
ated secondary antibodies for 1 h and then in horseradish
peroxidase-conjugated streptavidin for 1 h. After this process,
specific protein bands were detected with an enhanced
chemiluminescence system (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
Enzyme-Linked ImmunoSorbent Assay (ELISA)
The concentration of TTR protein in themedia of differentiated
FAP-specific iPS cells was measured by ELISA assay. The
differentiation medium was changed to fresh medium 48 h
before the assay. The wells of Nunc-ImmunoTM plate II (Thermo
Fisher Scientific) were coated with 7000-fold dilution of TTR
sheep anti-human polyclonal antibody (LifeSpan BioSciences,
Seattle, USA) in carbonate/bicarbonate buffer and incubated
overnight at 4 °C. The coating buffer was removed and the
wells were washed three times with 200 μl PBST. 250 μlblocking buffer and 0.5% gelatin in the coating buffer were
added per well and incubated for 1 h at room temperature. The
blocking buffer was removed and the wells were washed as
described above. 100 μl of appropriately diluted samples and
serum as the standard were added to each well and incubated
for 1 h at room temperature. The samples and standard were
removed and the wells were washed as described above. 100 μl
of 10,000-fold diluted polyclonal rabbit anti-human TTR
antibody (Dako) in 0.5% gelatin in the PBST was added to each
well and incubated for 1 h at room temperature. The detection
antibody was removed and wells were washed as described
above. 100 μl of 5000-fold diluted polyclonal goat anti-rabbit
immunoglobulins/HRP (Dako) in 0.5% gelatin in the PBST was
added to each well and incubated for 1 h at room temperature.
The secondary antibody was removed and the wells washed as
described above. 100 μl of TMB (KPL, Gaithersburg, USA)
solution was added to each well and 1 and half min later,
equal volume of stop solution (1 M HCL) was added and read the
optical density at 450 nm.Results
Generation of iPS cells from patients with FAP
Dermal fibroblasts obtained from heterozygotic FAP Val30Met
patients (Table 1) were cultured and infectedwith SeV vectors
encoding the reprogramming factors Oct3/4, Sox2, Klf4, and
c-Myc. Forms of TTR in the serum of one FAP patient (A002)
were analyzed by using SELDI-TOF MS, which detected peaks
of approximately 13,761 Da for wild-type TTR and 13,792 Da
for ATTR Val30Met (Fig. 1). The reprogrammed cells were
positive for ALP activity (Fig. 2A). RT-PCR confirmed the
expression of pluripotency markers such as NANOG and TERT
in FAP-specific iPS cells. SeV vectors were diluted during cell
growth and removed after the temperature shift treatment
(at 38 °C for 3 days) (Fig. 2B). Immunostaining with the
antibody against SeV protein demonstrated the clones free of
viral proteins (Fig. 2C). The reprogrammed cells exhibited the
ES-like morphology and the expression of pluripotency marker
Oct3/4 was confirmed by immunostaining (Fig. 2D). The
induction efficiency of FAP-specific iPS cells ranged from
0.054% to 0.41% for each individual (Table 1).
Figure 2 Efficient generation of FAP-specific iPS cells by SeV vectors. (A) ALP staining of cells growing on 100-mm dishes. (B) RT-PCR
analysis of expression of NANOG, TERT, SeV, and β-actin. iPS-1 to iPS-10 are established clones. (C) Typical staining of FAP-specific iPS
cell colonies with anti-SeV antibodies. The colony was partially positive (left panel) and negative (right panel) for SeV. BC, bright
contrast. Scale bar, 50 μm and 100 μm. (D) Immunostaining of established clones with pluripotency marker Oct3/4 (green). Nuclei were
stained with DAPI (blue). BF, bright field. Scale bar, 100 μm.
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hepatocyte-like cells
For cell differentiation, FAP-specific iPS cells were cultured
with serial changes of media as shown in Fig. 3A. To
test whether FAP-specific iPS cells can differentiate into
hepatocyte-like cells, we analyzed several markers via
real-time PCR analysis on Day 5 (D5), D13 and D20 differen-
tiated FAP-specific iPS cells (Fig. 3B). A decrease in expression
of the pluripotency marker Oct3/4 was accompanied by
differentiation of FAP-specific iPS cells. Expression of the
endoderm marker Sox17 was observed on D5 differentiation
and decreased gradually after the medium was changed to
hepatic differentiation medium on D7 (Fig. 3B). The hepatic
progenitormarker AFP and themature hepatocytemarker ALB
were obviously expressed on D13 and D20. In addition,
immunocytochemical analyses showed Sox17 expression on
D5, both HNF-4α and AFP expression on D13, and ALB
cytoplasmic staining on D20 (Fig. 3C). Quantitative imaging
analysis revealed that approximately 78 ± 0.6% of cells were
Sox17-positive on D5 and approximately 88 ± 1.1% of cells
were AFP-positive on D13 and approximately 29 ± 0.9% of cells
were ALB-positive on D20 (Fig. 3D). The ALB secretion in the
media of differentiated FAP-specific iPS cells on D20 was
approximately 20 μg/ml (Fig. 3E). Moreover, these D20
differentiated FAP-specific iPS cells were also periodic
acid-Schiff (PAS)-positive, indicating cytoplasmic glycogenstorage (Fig. 3F). These results clearly indicated that
FAP-specific iPS cells had the potential to differentiate into
hepatocyte-like cells.Production of wild-type TTR and ATTR Val30Met by
differentiated hepatocyte-like cells
We next sought to determine whether hepatocyte-like cells
differentiated from FAP-specific iPS cells would indeed
express TTR. Expression of TTR mRNA was detectable from
D13 (Fig. 4A). To confirm the presence of TTR protein,
Western blotting of culture supernatant was performed with
an anti-human TTR antibody. As Fig. 4B shows, expression of
TTR protein levels was confirmed in the concentrated D20
culture supernatant. The approximate concentration of TTR
protein in the media of differentiated FAP-specific iPS cells
was approximately 2.28 μg/ml (Fig. 4C). In addition, the
PCR-RFLP method showed that hepatocyte-like cells differ-
entiated from FAP-specific iPS cells indeed expressed ATTR
Val30Met and wild-type TTR mRNA, similar to expression in
the liver of the FAP patient from whom FAP-specific iPS cells
were generated (Fig. 5A). Moreover, LC–MS/MS analysis
clearly showed that hepatocyte-like cells differentiated
from FAP-specific iPS cells indeed expressed both ATTR
Val30Met and wild-type TTR at protein level and the ratio of
TTR protein to ATTR protein is approximately 1 to 1 in the
Figure 3 Differentiation of FAP-specific iPS cells. (A) Schematic of the experimental procedure. FAP-specific iPS cells were
differentiated on Day (D) 0 to Day 5 in DMEM supplemented with 100 ng/ml Activin and 2% B27 supplement. From D5 to D7, RPMI-1640
supplemented with 10 ng/ml BMP4, 10 ng/ml Fgf10, and 2% B27 supplement were used. At D7, the supplements were changed to
1 μM dexamethasone (Dex) and 10 ng/ml HGF in KSR with DMEM. (B) Quantification via real-time PCR analyses of the relative
expression levels of the pluripotency marker Oct3/4, the definitive endoderm marker Sox17, and the hepatic markers AFP and ALB in
differentiated FAP-specific iPS cells at D5, D13, and D20 and in undifferentiated iPS cells (Undiff) (n = 3). The expression levels were
normalized to that of GAPDH. RNA from 201B7 which were differentiated into hepatocyte-like cells the same as FAP-specific iPS cells
and the hepatic cell line HepG2 were examined as a positive control (n = 3). (C) Differentiated FAP-specific iPS cells on D5 were
stained for Oct3/4 (green) and Sox 17 (purple), D13 were stained for AFP (green) and HNF-4α (purple), D20 were stained for AFP
(green) and Albumin (purple). Scale bar, 100 μm. (D) FAP-specific iPS cells differentiated on D5, D13 and D20 were stained for Sox 17
(red), AFP (green) and ALB (red), and counterstained with DAPI (blue). Efficiency of differentiation assessed by dividing the number of
positive cells for Sox 17, AFP and ALB by the number of total cells (n = 3). Scale bar, 100 μm. (E) Albumin secretion by differentiated
FAP-specific iPS cells on D20 and undifferentiated iPS cells was measured (n = 3). The differentiation medium was changed to fresh
medium 48 h before the assay. (F) PAS staining of differentiated FAP-specific iPS cells on D20 indicated numerous hepatocyte-like
cells within the colonies with cytoplasmic glycogen storage. Scale bar, 100 μm.
580 K. Isono et al.D20 culture supernatant (Fig. 5B). Other FAP-specific iPS cell
lines also expressed both ATTR Val30Met and wild-type TTR
at protein level in the culture supernatant (data not shown).Discussion
In the present study, we generated iPS cells from patients with
FAP ATTR Val30Met by introducing four reprogramming factors
(Oct3/4, Sox2, Klf 4, and c-Myc) into dermal fibroblasts via SeV
vector infection. FAP-specific iPS cells had the potential to
differentiate into hepatocyte-like cells, a major TTR-producing
cell, and indeed expressed ATTR Val30Met and wild-type TTR
protein. FAP-specific iPS cells demonstrated the possibility ofserving as a pathological tool, which may contribute to
elucidating the molecular pathogenesis of FAP and developing
novel therapeutic strategies for FAP.
Attempts to establish the experimental models of FAP
(Buxbaum et al., 2003; Pokrzywa et al., 2007; Berg et al.,
2009) have not been as successful as researchers would wish.
It has been reported that transgenic mice overexpressing
mutated TTR did not display signs of neuropathology
(Buxbaum et al., 2003). It is still controversial whether the
pathogenic mechanism of FAP in Drosophila model is in the
same manner as human (Pokrzywa et al., 2007; Berg et al.,
2009). In addition, a review of previous studies about the
molecular pathogenesis of FAP indicates that most of the
studies investigated the pathologic effect of ATTR using
Figure 4 TTR expression in differentiated FAP-specific iPS cells. (A) Quantification via real-time PCR analyses of the relative
expression levels of TTR mRNA in differentiated FAP-specific iPS cells on D5, D13, D20, and 201B7 on D20 and in undifferentiated iPS
cells (Undiff) (n = 3). The expression levels were normalized to that of GAPDH. (B) TTR protein expression determined in the D20
supernatant by Western blotting with anti-TTR polyclonal antibody. (C) TTR secretion by differentiated FAP-specific iPS cells on D20
and undifferentiated iPS cells was measured by ELISA assay (n = 3).
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(Sousa et al., 2000; Cardoso et al., 2008; Sato et al., 2007).
Indeed, the neurodegeneration induced by ATTR or endo-
plasmic reticulum quality control of ATTR was studied with
non-mutant mammalian cells transfected with the receptor
for advanced glycation end products (Sousa et al., 2000)
or wild-type TTR and ATTR (Sato et al., 2007). Because
FAP is an autosomal-dominant hereditary disease and thoseFigure 5 TTR and ATTR expression in differentiated FAP-specific iP
of differentiated hepatocyte-like cells on D20. Arrows indicate the w
after digestion with the Nsi1 restriction enzyme. The liver of the FA
MS/MS analysis of the D20 culture supernatant showed both TTR and
Asterisks indicate the ATTR Val30Met peaks.systems did not utilize heterozygous ATTR mutant cell models,
those systems do not fully represent the relevant processes in
patients with FAP and are unsuitable for evaluation of therapy.
The ratio of expression of TTR protein to ATTR protein varies
among cells. As with iPS cells designed to be specific for other
diseases, iPS cells generated from patients who were
heterozygous for FAP are more useful for elucidating the
pathogenesis of FAP: TTR and ATTR in heterozygous FAP formS cells. (A) PCR-RFLP analysis of TTR and ATTR mRNA expression
ild-type TTR peaks. Asterisks indicate the ATTR Val30Met peaks
P patient (A002) and HepG2 cells was used as a control. (B) LC–
ATTR at protein levels. Arrows indicate the wild-type TTR peaks.
582 K. Isono et al.heterotetramers, which produce amyloid, and recombinant
TTR forms a homotetramer, which is a totally different form of
TTR in plasma and tissues. Generation of various FAP-specific
iPS cells may help clarify the mechanism of the phenotypic
variations among individuals with the same genotype
(Kato-Motozaki et al., 2008) and the cellular and molecular
pathogenesis. In this study, hepatocyte-like cells differenti-
ated from FAP-specific iPS cells indeed secreted TTR and ATTR
protein in the ratio of almost 1 to 1 as heterozygous ATTR
mutant cells (Fig. 5B). The amount of TTR protein was
approximately 2.28 μg/ml (Fig. 4C), which is comparable
with the previous result (0.2–2 μg/ml) in functional
hepatocyte-like cells differentiated from normal iPS cells
(Sullivan et al., 2010), and exhibits 50 times higher than the
previous result (0.034–0.057 μg/ml) in human hepatocytes in
primary culture (Wigmore et al., 1997). Moreover, differen-
tiation of the same FAP-specific iPS cell line into various cells
such as neurons and cardiomyocytes may aid understanding of
the tissue selectivity of amyloidosis, which differs according to
variants (Hammarstrom et al., 2003; Sekijima et al., 2003;
Yamashita et al., 2005). Studies of other FAP-specific iPS cell
lines generated from TTR variants other than the Val30Met
mutation are currently in progress. FAP-specific iPS cells may
also be used for screening novel drug candidates such as
inhibitors of amyloid formation. Additional investigations are
needed to evaluate the phenotype of FAP-specific iPS cells in
greater detail and confirm the value of these cells as a novel
experimental tool of FAP.
In this study, we took full advantage of the special
characteristics of this SeV vector to establish FAP-specific iPS
cells. Because SeV vectors replicate only in the cytoplasm of
infected cells and do not integrate into the host genome (Li et
al., 2000), no risk of modifying the host genome exists. Using
retrovirus or lentivirus vectors results in integration of viral
transgenes into the host genome, which includes a risk of
tumorigenicity (Hussein et al., 2011; Gore et al., 2011). To solve
this problem, plasmids (Okita et al., 2008), a Cre/loxP system
(Soldner et al., 2009), adenoviruses (Stadtfeld et al., 2008),
piggyback (Woltjen et al., 2009), a minicircle vector (Jia et al.,
2010), and proteins (Zhou et al., 2009) have been developed.
The risk of integration into the genome still remains, however,
for DNA-type vectors (Harui et al., 1999), and those methods
also demonstrated low induction efficiency. Thus, the SeV
vector that we used is believed to have a significant advantage
compared with available methods because of its safety,
efficiency, and convenience. SeV vectors are slowly diluted
and disappear during iPS cell division, and SeV vector-positive
cells can be removed by means of an anti-SeV-HN antibody
(Fusaki et al., 2009). Moreover, with the temperature-sensitive
SeV vector used in this study, vectors, even if present, could
easily be removed after the temperature shift treatment and
would not be reactivated in iPS cells (Ban et al., 2011).
FAP-specific iPS cells would thus be safe andmay be a source for
cell replacement therapy.Conclusions
We successfully generated, for the first time, FAP-specific
iPS cells. Such FAP-specific iPS cells may serve as valuable
experimental tools to clarify the molecular pathogenesis of
FAP, with potential value in cell therapy applications.Acknowledgments
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